Overview Financials News + Filings Key Docs Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| | 10-K | 10-K | 10-K | 10-K | S-1 |
| Revenues: |
| Diagnostic test revenue | 227.3 | 205.1 | 175.4 | | |
| Self-pay patients | 7.6 | 3.8 | 2.0 | | |
| GeneDx | 122.2 | 7.1 | 4.0 | | |
| Total revenues | 234.7 | 212.2 | 179.3 | 196.2 | 133.3 |
| Revenue growth [+] | 10.6% | 18.3% | -8.6% | 47.1% | |
| Diagnostic test revenue | 10.8% | 17.0% | | | |
| Self-pay patients | 99.3% | 90.5% | | | |
| GeneDx | 1622.8% | 78.7% | | | |
| Cost of goods sold | 261.4 | 228.8 | 175.3 | 113.4 | 92.1 |
| Gross profit | -26.8 | -16.6 | 4.0 | 82.8 | 41.2 |
| Gross margin | -11.4% | -7.8% | 2.2% | 42.2% | 30.9% |
| Selling, general and administrative [+] | 338.2 | 318.7 | 163.9 | 68.8 | 39.4 |
| Sales and marketing | 134.9 | 112.7 | 63.2 | 39.4 | 19.9 |
| General and administrative | 203.3 | 206.0 | 100.7 | 29.5 | 19.4 |
| Research and development | 86.2 | 105.2 | 72.7 | 34.9 | 21.4 |
| Other operating expenses | 6.3 | 5.7 | 9.4 | 9.5 | 9.1 |
| EBITDA [+] | -398.2 | -424.3 | -230.3 | -24.0 | -23.2 |
| EBITDA growth | -6.2% | 84.3% | 859.2% | 3.3% | |
| EBITDA margin | -169.7% | -200.0% | -128.4% | -12.2% | -17.4% |
| Depreciation and amortization | 59.3 | 21.8 | 11.7 | 6.4 | 5.4 |
| EBIT [+] | -457.5 | -446.1 | -242.0 | -30.4 | -28.7 |
| EBIT growth | 2.5% | 84.4% | 695.7% | 6.1% | |
| EBIT margin | -194.9% | -210.3% | -134.9% | -15.5% | -21.5% |
| Non-recurring items [+] | 210.1 | | | | |
| Asset impairment | 210.1 | | | | |
| Interest expense, net [+] | 0.7 | 2.8 | 2.0 | -0.9 | 0.2 |
| Interest expense | 3.2 | 2.8 | 2.5 | 0.1 | 0.2 |
| Interest income | 2.5 | 0.1 | 0.5 | 1.0 | |
| Other income (expense), net [+] | 70.3 | 203.5 | 2.6 | -0.2 | 5.0 |
| Gain (loss) on debt retirement | | | | | 4.5 |
| Other | 0.1 | 5.1 | 2.6 | 0.5 | 0.5 |
| Pre-tax income | -598.0 | -245.4 | -241.3 | -29.7 | -23.9 |
| Income taxes | -49.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 8.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -549.0 | -245.4 | -241.3 | -32.7 | -26.8 |
| Net margin | -233.9% | -115.6% | -134.6% | -16.7% | -20.1% |
| |
| Basic EPS [+] | ($1.63) | ($2.27) | ($47,035.67) | ($264,056.45) | ($26,823,000.00) |
| Growth | -28.4% | -100.0% | -82.2% | -99.0% | |
| Diluted EPS [+] | ($1.63) | ($2.27) | ($47,035.67) | ($264,056.45) | ($26,823,000.00) |
| Growth | -28.4% | -100.0% | -82.2% | -99.0% | |
| |
| Shares outstanding (basic) [+] | 337.8 | 108.1 | 0.0 | 0.0 | 0.0 |
| Growth | 212.6% | 2106262.1% | 4037.9% | 12300.0% | |
| Shares outstanding (diluted) [+] | 337.8 | 108.1 | 0.0 | 0.0 | 0.0 |
| Growth | 212.6% | 2106262.1% | 4037.9% | 12300.0% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|